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Yttrium-90-EDTMP: a radiotherapeutic agent in the treatment of
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Sm_nuary Yttrium-90 chelated by the tetraphosphonate EDTMP achieved a high uptake in bone and a rapid
clearance from all soft tissues compared with 90Y nitrilotriacetate, citrate and acetate. The biological half-life
of 90Y in the bone was greater than 72h. but the quantity, and therefore dose, could be reduced by 50%
using repeated, non-toxic chelation therapy with the calcium salt of DTPA. This treatment should be able to
supplement current treatments for leukaemia where the dose of external beam radiation is associated with
considerable morbidity.
Radiotherapy followed by allogeneic bone marrow trans-
plantation is now a common procedure in the curative
therapy of leukaemias. The amount of radiation which can
be administered is limited by toxicity to certain radiosensitive
soft tissues such as the lungs and gut. Shielding the lungs
would unavoidably reduce the dose to leukaemic cells in the
ribs and thus increase the possibility of relapse. Radioiso-
topes which can be targeted specifically to the skeleton offer
attractive alternatives for marrow ablation, or alternatively
they could be used in conjunction with lower dose external
beam radiotherapy.
Such isotopes are now also under investigation for the
palliation of bone pain associated with metastatic deposits of
tumours of the breast and prostate and from pnrmary
osteosarcoma. These include 1311 (as diphosphonate;
Eisenhut et al., 1986), 89Sr (as the free ion; Blake et al.,
1987) and '53Sm (as the tetraphosphonate complex; Goeck-
eler et al., 1987), which localise efficiently in the bone and
are cleared rapidly from all soft tissues. Successful pain
reduction has been reported for all three isotopes,
and in addition 89Sr has demonstrated enhanced
uptake in certain osteoblastic tumours. Palliation results
from toxic radiation doses to the periphery of the tumours
from the isotopes deposited on hydroxyapatite mineral sur-
faces. Because of their low energies, the beta particle emis-
sions from these isotopes have limited penetration into
tumours or bone marrow spaces. However, 89mr a
= 1.5 MeV) has been shown to ablate medullary haemo-
poietic tissue at doses above 4yCi per g body weight in mice
in several investigations (Klassen et al., 1972; Adler et al..
1977). A limitation to the clinical use of 89Sr, and also '31I
results from a combination of their long physical half-lifes
(50 and 7 days respectively), and long biological half-lives in
bone. These factors prevent prompt bone marrow transplan-
tation and graft establishment. For successful leukaemia and
marrow ablation in humans, isotopes with substantially
shorter half-lives and higher # particle energies are required.
Yttrium-90 is a high energy (2.3 MeV) beta emitter with a
physical half-life of 2.7 days which has limited bone-seeking
properties. Its physical properties make it ideal for therapeu-
tic applications, the most energetic beta emission being able
to penetrate to 1 cm from the site ofdeposition in soft tissue,
with an average range of approximately 4mm. Theoretically,
therefore, it can penetrate all marrow spaces in normal
trabecular bone and conceivably even to the centre of large
tumours where bone destruction may be extensive. A disad-
vantage of yttrium-90 is its tendency to accumulate in the
reticuloendothelial system as well as hydroxyapatite surfaces,
due to the formation of colloidal hydroxide or yttrium-
transferrin complexes, followed by transport to the liver. The
previous very limited studies of yttrium-90 (Dudley &
Greenberg, 1956; Kutzner et al., 1983) have failed to reduce
significantly the reticuloendothelial uptake, and its use as a
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radiotherapeutic bone agent has been disregarded in recent
years. Since marrow ablative radiotherapy is becoming
increasingly common in the management of leukaemia, there
would appear to be a place for an isotope with the charac-
tenstics of 90Y.
Specific deposition of yttrium into the skeleton demands
its delivery in a chemical form with affinity for bone mineral
alone. In the past, this has been difficult to achieve because
even when chelated, liver uptake has been substantial,
presumably because the stabilities of the complexes are insuf-
ficient to prevent transferrin binding or colloid formation in
vivo. Ideally therefore, targeting agents are required with an
intrinsically high affinity for bone, and also a high affinity
for the yttrium ion. Compounds with these properties are the
phosphonate analogues of polyaminocarboxylic acids, and
one in particular (ethylene diamine tetra methylene phospho-
nate; EDTMP) has already been used to target 153Sm to
bone mineral with considerable success (Goeckeler et al..
1987). Because of chemical similarities between yttrium and
the rare earths, EDTMP should form stable complexes with
yttrium and carry it- specifically to the bone with comparable
efficiency. Here, 90Y-EDTMP complexes have been prepared
and compared with other chelating agents for targeting 90Y
to the bone in vivo. Similar experiments are also described
using the gamma-emitter yttrium-88 to determine the effects
of carrier yttrium on tissue distnrbution.
The adsorption of yttrium on hydroxyapatite is essentially
irreversible under static conditions but elution in vivo is
determined by rates of mineral resorption and new-bone
formation. When considering its use in leukaemia therapy
and bone marrow ablation, it would be advantageous to
control the bone marrow dose by removing yttrium from the
bone. Early studies aimed at lowering skeletal contamination
by yttrium produced in nuclear accidents used repeated
EDTA injections, and over a 14-day period, skeletal uptake
was reduced to 70% of the control values (Cohn et al..
1953). Conventionally, diethylene tnramine pentaacetic acid
(DTPA) has been the agent of choice for the treatment of
heavy metal overdose (Catsch, 1961), and yttnrum also has a
high affinity for this chelator. A further aim of this work
was to manipulate the biological half-life of 90Y and 88Y in
bone by chelation therapy using DTPA, and determine the
amount of isotope that could be removed from skeletal
tissue.
Materials and methods
Production of carrier-free yttriwn-90
A Dowex 50W-X8 cation exchange column was loaded with
,20pCi 90Sr-mntrate and washed extensively with citric acid
and 0.25M sodium acetate, pH6 as described by Vaughan et
al. (1985). It was then left for at least 5 days to allow
equilibration between 90Sr and its daughter 90Y. The column
was eluted with 0.25M sodium acetate pH6. Eluted counts
were usually due to pure 90Y, but on occasion a 90Sr
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Figue 1 Effect of citrate chelator on the distribution of tracer
camer free 90Y in the bone (0), kidney (0) and liver (-) of
BALBtc mice at 24h after i.p. injection. n=3 for each point
(n=2 for 3 x 10-6mol citrate dose) ±s.e.
breakthrough of - 2% was observed. The eluted 90Y acetate
was used in subsequent preparations for injection into
BALB/c mice.
Preparation of vttriwn isotope complexes and DTPA solutions
Complexes of 90Y with the chelating agents citrate, nitrilotnr-
acetate (NTA) and EDTMP were prepared. Up to 3pCi of
90Y in acetate were added to solutions of tnrsodium citrate,
and trisodium NTA (0.03ml) to give 1.5 x 10-5, 3 x 10-6
and 3 x 10-7 mol of chelator per injection. The volume of
the injection was made to 0.18ml with phosphate-buffered
saline. EDTMP was a gift from Albright and Wilson Ltd
and supplied at a purity of at least 92.7%, the main contami-
nant being ethylene diamine trimethylene phosphonate. It was
used at concentrations of 0.54mM (pH4.5) and 54mM
(pH 3.9). Volumes of these solutions were added to 2pCi
90Y to give 3.54x 10-8 or 1.77x 10-6mol per injection in a
final volume of 0.18ml, the remaining volume being made
up with 0.25M sodium acetate pH 5.9 and water.
The complex of yttrium-88 with EDTMP was also
prepared in order to compare biodistributions with those of
90Y. Yttrium-88 (0.3pCi in 5pi 0.25 M acetate pH6;
Amersham, 0.98mCi pg-1) was chelated with volumes of
0.5M EDTMP (pH6.95 in 0.5M sodium chloride) after the
addition of non-radioactive yttrium chloride to give either a
2-fold or 1.2-fold molar excess of EDTMP over yttrium.
Immediately upon addition of EDTMP to the yttrium
solution, a white precipitate formed which redissolved over a
10-min period. These solutions were diluted with 0.25M
sodium acetate pH6 to give final volumes of around 0.3ml.
They were used to evaluate the effect of increasing doses
over carrier yttrium and EDTMP concentration on the
biodistribution of yttrium in mice.
The calcium salt of DTPA was prepared by dissolving
sodium chloride, sodium bicarbonate, calcium carbonate and
DTPA in water to give 0.034M Na3CaDTPA in 0.9% saline
(pH 8). Any remaining solid material was filtered prior to
injection into animals. The sodium salt of DTPA was
prepared by dissolving sodium hydroxide, DTPA and
sodium chloride in water to give 0.034M DTPA in saline,
pH7.2.
Biodistribution studies in BALB/c mice
The biological distribution 90Y was assessed for each chelat-
ing solution to determine the chemical forms most suitable
to achieve high skeletal uptake and low reticuloendothelial
uptake. All injections were i.p. in male BALB/c mice weigh-
ing between 18 and 28g. Animals were killed at various
times after injection, and samples of various tissues weighed.
Water (1 ml) was added to each sample before counting for
brehmsstrahlung emission on a Packard Autogamma counter
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Figre 2 Effect of nitrilotriacetate (NTA) chelator on the distri-
bution of tracer, carrier-free 90Y in the bone (-), kidney (0)
and liver (-) of BALB/c mice at 24h after i.p. injection. n=3 for
each point, +s.e.
(lower detection limit= 15keV, upper detection limit=
2MeV). The quantity of yttnrum-90 in each tissue was
determined in per cent injected dose (ID) per gram after
correcting for physical half-life, counting geometry, and
where necessary, 90Sr contamination. The presence of 90Sr
was deduced from the physical decay of samples of generator
eluates, and calculated assuming constant 90Sr counts over
the period of observation (up to one week). Since about 50%
of 90Sr localises in the skeleton and the remainder is rapidly
excreted, it was assumed that 20% per g of injected 90Sr was
deposited in the skeleton, accounting for 180-200c.p.m. in
the final bone counts, with negligible counts in soft tissue.
The biodistribution of 88Y-EDTMP was determined in the
same way except that injection volumes were 0.3ml. Tissues
were similarly counted but without the need for addition of
water or correction due to counting geometry and 90Sr
contamination.
The effect of DTPA on the biodistribution of both 90Y
and 88Y was determined. Animals received an i.p. injection
of 90Y-EDTMP or 88Y-EDTMP, and the following day
either DTPA (0.2ml, 6.8pmol, test animals) or physiological
saline (0.2ml, controls). Several experiments were carried out
in which animals were treated with up to eight DTPA
injections over up to 4 days. Animals were killed at least
15h after the final DTPA/saline injection, tissues being
weighed and counted as described above, and the necessary
corrections made to determine counts in %IDg-1 tissue.
The significance of differences between treated and control
counts in each tissue was calculated using a one-tailed
Student's t test.
Dosimetry
Radiation doses to the skeleton in 25g mice assuming 20%
IDg- were calculated using a computer model already
described by Vaughan et al. (1987), and modified to estimate
bone marrow doses as described by Spiers (1978). The effects
of CaDTPA chelation therapy were calculated similarly but
including the decorporation data. Calculations were based
on the following assumptions: (a) tl'2 of skeletal accumula-
tion=0.5h; (b) no isotopic excretion from the skeleton under
usual physiological conditions; (c) tl 2 for whole body excre-
tion=5 h. Calculations of the effects of CaDTPA assumed a
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Figure 3 Biodistribution of tracer quantities of carrier-free 90Y
in BALB/c mice after chelation with EDTMP at two concen-
trations (I) 3.54x 108mol: bone (0), kidney (U), liver ( x); (2)
1.77 x 10-6mol: bone(O), kidney(L]), liver(*). *n=2 animals
mobilisation of 8.5% of the yttrium, and hence an 8.5%
reduction in radiation dose (cGyh-1), per DTPA injection
for six injections.
Results
With all the chelating agents tested, 90Y demonstrated a
high absolute uptake in bone mineral. This was the case for
tracer levels of carrier-free isotope. However, over the range
of tested concentrations, citrate failed to significantly reduce
reticuloendothelial uptake (Figure 1) and NTA failed simi-
larly at low chelator concentrations, compared with unche-
lated isotope (Figure 2). At the highest concentration tested,
NTA suppressed both reticuloendothelial and bone mineral
accumulation. This was also at a concentration which could
prove unacceptably toxic if scaled up for clinical use. Over a
range of concentrations, EDTMP enabled consistently high
bone uptakes and low kidney and liver accumulation (Table
I and Figure 3). Because of its consistency in giving high
bone to soft tissue uptake ratios compared with other
targeting agents, EDTMP was considered the reagent of
choice for the specific delivery of 90Y to bone mineral,
though absolute skeletal uptake was marginally lower
(Figure 4). With EDTMP, the biological half-life in the liver
1A
Kidney Liver
24-h biodistribution
Fgue 4 Comparison of 24h tissue distnrbutions of camrer free
Y after complexation with 3.54x 10-8mol EDTMP lE. 3x
10-7mol NTA(=l), 3 x 10`6mol citrate ( D) and uncomplexed
in 0.25M acetate ( ). n=3 for each bar, +s.e.
and kidney was approximately 24h, while the biological half
life in bone was well in excess of 72h (estimates derived
from Figure 3).
The effect of increasing the doses of non-active yttrium
and EDTMP were determined for 88Y-EDTMP as shown in
Table II. With total doses of yttrium above 50 pg per animal,
the biodistribution of the isotope was significantly altered,
the total bone uptake being approximately halved at 200 or
500pg of yttnrum per injection with EDTMP to Y ratios of
2: 1. However, reduction of the EDTMP to Y ratio to 1.2:1
substantially restored bone uptake, but kidney clearance at
24h was also increased; a frequent observation when more
than 200pg of yttrium per animal was injected, suggesting
that available skeletal adsorption sites were saturated for Y-
EDTMP doses in excess of 200pg.
DTPA chelation therapy was carried out in animals given
90Y-EDTMP and 88Y-EDTMP. In all cases DTPA treat-
ment was commenced about 20h following injection of
isotope to allow maximal early skeletal accumulation. Ani-
mals given two injections of CaDTPA per day showed no ill
effects of the treatment, even when given repeatedly over a
4-day period. There was no evidence of body weight loss or
bone decalcification as judged by femora weights at death,
compared with untreated animals. Sodium DTPA when
injected i.p. did not demonstrate enhanced clearance when
compared with CaDTPA. The clearance of yttnrum from
Table I Biodistribution in BALB/c mice of trace doses of 90Y complexed with two concentrations of EDTMP
% ID g-1 tissue at times after i.p. injection (+s.e., n=3) (boneltissue ratio in parentheses)
Mol EDTMP Tissue 3h 24h 48h 72h
3.54 x 10- Blood 0.006+0.005 (2,300t 0.003+0.002 (6,200) 0.004+0.005 (3,700) 0.004+0.003 (3,600)
Bone 13.77 +1.85a 18.54 +2.41 14.81 +2.36 14.41 +1.52
Kidney 0.92 +0.10 (15t 0.46 +0.03 (40) 0.33 +0O006 (45) 0.20 +0.01 (72)
Liver 0.51 +0.0 (27r 0.34 +0.03 (55) 0.20 +0.00 (74) 0.16 +0.006 (90)
Lung 0.10 +0.04 (138t 0.21 +0.17 (88) 0.03 +0.01 (490) 0.03 +0.01 (490)
Spleen 0.16 +0.01 (86r 0.09 +0.02 (206) 0.02 +0.02 (740) 0.04 +0.03 (360)
1.77 x 10-6 Blood 0.04 +0.02 (250) 0.01 +0.006 (1,030) 0.003+0.002 (4,300) 0.008+0.006 (1,300)
Bone 9.95 + 1.22 10.33 +0.52 12.80 + 1.57 10.39 + 1.47
Kidney 0.70 +0.10 (14) 0.24 +0.02 (43) 0.15 +0.003 (85) 0.12 +0.006 (87)
Liver 0.09 +0.01 (110) 0.06 +0.002 (170) 0.07 +0.01 (183) 0.05 +0.006 (210)
Lung 0.11 +0.03 (90) 0.02 +0.01 (516) 0.02 +0.01 (640) 0.03 +0.01 (350)
Spleen 0.10 +0.05 (100) 0.03 +0.01 (340) 0.05 +0.02 (260) 0.06 +0.03 (170)
'n=2 animals.
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Fgwe 5 Estimated radiation dose rates to bone marrow
(cGyh MBq-1) in mice 90Y-EDTMP (a) and 90Y-EDTMP
followed by chelation therapy with CaDTPA (b).
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Fgwe 6 Estimated cumulative radiation doses in bone marrow
(GyMBq-)'in mice given 90Y-EDTMP (a) and 90Y-EDTMP
followed by chelation therapy with CaDTPA (b).
Table I Biodistribution of 88Y-EDTMP with increasing doses of carrier yttnium at 24h
after i.p. injection
% ID g-' tiue over a range ofyttriwm concentrations+s.e.
(EDTMP: Y=2:1)
Tissue 50g Y (n=3) 2(00M _Y (n=3) 200()g y' (n=3) 500Xpg Y (n=6)
Blood 0.02+0.01(793) 0.00 +0.00 (x) 0.02+0.003(557) 0.05+ 0.05(146)
Bone 15.96+1 26 8.45 +0.77 13.28+1.04 7.29+ 0.95
Kidney 0.35±0.02 (45) 1.57 +0.67 (5.4) 5.45±2.20 (2.4) 24.78+17.20 (0.3)
Liver 0.17+0.03 (93) 0.10 +0.02 (85) 0.47±0.07 (28) 0.25+ 0.15 (29)
Lung 0.06+0.01(264) 0.07 +0.02 (120) 0.42+0.21 (32) 0.15+0.10 (49)
Muscle 0.03+0.02(529) 0.004+0.003(2,100) 0.70+0.03 (195) 0.04+ 0.02(182)
Spleen 0.18+0.05 (88) 0.10 +0.04 (84) 0.59+0.14 (23) 0.35+ 0.27 (21)
Except where shown ('), EDTMP:yttrium ratio=2:1. Mean bone to soft tissue uptake
ratios are shown in parentheses 'EDTMP:Y=12:1.
Ta&be m Effects of DTPA chelation therapy on tissue retention of
90Y and 88Y in BALB/c mice after i.p. injection
% injected dose per g tissue (s.e.)
Experiuent Bone Kidney Liver
1. 5 x CaDTPA 13.63(1.63) 0.20(0.004) 0.09(0.01)
Control 18.79(0.88) 0.28(0.02) 0.16(0.01)
Test/control 0.73' 0.71 0.56
2. 5 x NaDTPA 9.68(0.81) 0.16(0.01) 0.05(0.01)
Control 13.27(1.79) 0.21(0.02) 0.13(0.01)
Test/control 0.73b 0.62 0.34
3. 6 x CaDTPA 10.75(0.79) 0.07(0.01) 0.05(0.01)
Control 21.57(1.96) 0.23(0.04) 0.17(0.02)
Test/control 0.50 0.30 0.29
4. 8 x CaDTPA 10.00(1.40) 0.12(0.01) 0.04(0.004)
Control 20.02(1.86) 0.21(0.01) 0.13(0.01)
Test/control 0.50 0.57 0.31
5. 8 x CaDTPA 6.15(0.74) 0.06(0.01) 0.05(0.01)
Control 9.53(1.30) 0.13(0.01) 0.12(0.01)
Test/control 0.64b 0.46 0.42
Expt 1. Animals received 90Y-EDTMP on day 1. Tests received
3x6.8anol CaDTPA on day 2, 2x6.8pmol CaDTPA on day 3,
animals killed and tissues counted on day 4. Controls received saline
instead of DTPA.
Expt 2. Animals received 90Y-EDTMIP on day 1. Tests received
3x6.8npol NaDTPA on day 2, 2x6.8pmol NaDTPA on day 3,
animals killed and tissues counted on day 4. Controls received saline
instead of DTPA.
Expt 3. Animals received 90Y-EDTMP on day 1. Tests received
2 x 6.8pmol CaDTPA on days 2, 3 and 4, animals killed and tissues
counted on day 7. Controls received saline instead of DTPA.
Erpt 4. Animals received 90Y-EDTMP on day 1. Tests received
2x6.8kumol CaDTPA on days 2, 3, 4 and 5, animals killed and
tissues counted on day 6. Controls received saline instead of DTPA.
Expt 5. Animals received 88Y-EDTMP (50jug yttrium; EDTMP to
Y ratio=2:1), on day 1. Tests received 2x6.8pmol CaDTPA on
days 2, 3. 4 and 5, animals killed and tissues counted on day 6.
Controls received saline instead of DTPA.
All treated tissues highly significantly lower % IDg- 1 than
controls (P<0.01), except 'P<0.05 and bp>005 i.e. not significant;
n=5 mice for each treatment.
both the bone mineral and the kidney and liver by CaDTPA
was dependent on the number of doses given (Table III).
Maximum removal from the tissues in test animals compared
with control animals was achieved by giving 2 x 6.8 umol
CaDTPA daily over 3 days. In most cases, the treated
animal tissue counts were significantly lower than the
controls as judged by a one-tailed t-test. There was no
improved clearance beyond this by giving 2 x 6.8 umol daily
for 4 days. For high quantities of carrier yttrium (50pg)
there was no significant mobilisation of activity from the
skeleton with the same CaDTPA treatment regimen. The
apparent maximum proportion of isotope cleared from the
bone was 50% and from the kidney and liver approximately
70% in the optimum cases. This maximum mobilisation
could be achieved by 5 days from the initial isotope
injection.
Radiation doses administered by 90Y-EDTMP to the bone
marrow were expressed as either cGyh - MBq-I (Figure 5)
or cumulative doses (Gy total MBq-1, Figure 6). Calcium
DTPA reduced the dose but no decorporation effects were
observed subsequent to six CaDTPA injections.
Discws
Yttnrum-90 has been selectively targeted to bone in mice
using citrate, the tricarboxylate NTA and EDTMP. It was
found that all reagents successfully enabled bone deposition
but EDTMP gave the lowest corresponding doses to all soft
tissues. This was due to the high stability of the yttrium-
EDTMP complex allied to the natural bone-seeking qualities
of EDTMP. It showed a very similar biodistribution to the
lanthanide isotope EDTMP complexes (Goeckeler et al.,
1987; Appelbaum et al., 1988). Yttrium-EDTMP itself has a
high affinity for bone comparable with the diphosphonates,
as shown by previous studies with other isotopes in rats
(Goeckeler et al., 1987). Similar bone accumulation by the
complex was shown over a range of 90Y-EDTMP concen-
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trations. With NTA. the bone targeting effect was due
entirely to the prevention of radiocolloid formation allied to
the affinity of the tnrpositive yttrium ion for bone, which
varied according to the concentrations of both yttrium and
NTA. The reduction in bone accumulation observed using
high chelating concentrations of NTA is probably due to
slower dissociation or faster re-formation of the chelate.
retarding transfer to bone. This has been already suggested
for the similar lutetium-177-NTA complex from in vitro
experiments (Keeling & Vaughan. 1988).
The results of yttrium targeting described are applicable to
both trace quantities of carrier-free isotope and for prepar-
ations containing quantities of non-active material, though
the chelate to yttrium ratio does affect bone targeting at high
levels of yttrium carrier. The reduction in bone uptake and
increased excretion can be attributed to the saturation of
adsorption sites in the skeleton. For producing therapeutic
millicurie doses, the 90Sr/90Y generator system (Vaughan et
al.. 1985) may not be ideal because of 90Sr contamination.
Yttrium-90 is available from Amersham at a specific activity
of l-IOmCimg-' yttrium. Since the bone targeting of Y-
EDTMP is not as efficient when high quantities of carrier
yttrium or EDTMP are used, high specific activity material
is desirable for further animal and preliminary clinical
investigations. Such high specific activity material is available
from Oak Ridge National Laboratory (TN. USA).
EDTMP is currently the complexing agent of choice for
delivering 90Y to the skeleton for clinical radiotherapeutic
applications, as for the similar lanthanide elements 153Sm
and '66Ho. The isotope of choice for myeloablative appli-
cations remains uncertain at present but there are arguments
in favour of yttrium-90. Preliminary reports of the use of
166Ho-EDTMP for myeloblation in dogs (Appelbaum et al.,
1988) were encouraging, doses of above 300mCi of the
isotope inducing lethal asplasia which could be prevented by
the administration of autologous bone marrow seven days
after isotope injection. This was enabled by the high fi-
energy (Epi.m = 1.9MeV) and short half-life (26h) of the
isotope. A disadvantage of holmium-166 for clinical appli-
cations is the considerable external radiation dose hazard
arising from the isotope's gamma-emission, and the difficulty
of producing and transporting the material to the site of
injection without loss of the isotope due to physical decay.
Doses above 1 Ci would be required to induce marrow
ablation in humans and these could prove unacceptable in a
standard hospital environment.
Yttrium-90 would similarly be able to deliver myeloablative
radiation doses. However, its higher f-energy (Eha=
2.3 MeV) would achieve more effective penetration of
tumour tissue in areas of extensive bone destruction and give
improved cell kill in either leukaemia or solid tumours.
However, the long half-life of yttrium (2.7 days) compared
with '66Ho (26h) could compromise donor marrow engraft-
ment. The percentage of initial counts remaining in the bone
7 days after injection would be approximately 1% for '66Ho
and 16% for 90Y, assuming rapid uptake in bone and an
infinite biological half-life. The administration of calcium
DTPA after targeting of 90Y to bone can reduce this by
50% or more by repetitive administration. This level of 90Y
may prove low enough to allow successful subsequent donor
tissue engraftment. The absence of gamma-irradiation from
90Y reduces the external dose hazard to workers and the
longer half-life means that considerably lower activities
would be administered than with 166Ho.
In order to determine the efficacy of 90Y marrow ablation
and subsequent donor engraftment, an appropriate system is
available in congenic CBA mice which possess different
alloenzymes of glucose phosphate isomerase and phospho-
glycerate kinase (Ansell & Micklem, 1986). The alloenzymes
possess different electrophoretic mobilities and the degree of
chimerism that can be achieved in haemopoietic cell popula-
tions is a measure both of ablation of host tissue and the
effective engraftment of donor haemopoietic tissue. This
system will be used to investigate myeloablation and recovery
of donor-treated mice after treatment with high doses of
90Y-EDTMP. Clinically, the biological distribution of the
EDTMP complex of yttnrum can be determined using the
isotope 87y, which possesses gamma-rays suitable for con-
ventional planar imaging. The efficacy of DTPA chelation
therapy could also be assessed in humans by nuclear medical
scanning procedures.
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